Background/Aim: Imatinib (IM) is the standardof-care treatment for most chronic myeloid leukemia (CML) patients in chronic phase (CP). However, some patients suffer from low-grade side-effects that, in the long run, severely affect the quality of life and require treatment discontinuation due to toxicities. Fortunately, there are several therapeutic alternatives for these patients. Among them, the secondgeneration tyrosine kinase inhibitor dasatinib (DAS), used as second-line treatment, has shown to be a valid option in patients with CP-CML after intolerance to prior IM. Patients and Methods: Herein, we report on seven CP-CML patients who achieved a stable major molecular response (MMR) with IM-therapy, but were shifted to DAS treatment due to recurrent low-grade IM-intolerances (grades 1-2). Results and Conclusion: All patients received conventional DAS treatment with a median daily dose of 83.3 mg. Treatment was well tolerated and side-effects were mild. In addition, after a median follow-up of 25 months (range=24-43 months) a deep molecular response (DMR) (either MR 4 or MR 4.5 ) was achieved in all patients after 24 months of treatment. This finding, although limited to a small cohort of CP-CML patients, supports the view that a therapy switch from IM to DAS induces a reduction of symptom burden, improves patient compliance and shows clinical efficacy in achieving and sustaining deep molecular responses.The clinical scenario of chronic myeloid leukemia (CML) has changed significantly, since the introduction of tyrosine kinase inhibitors (TKIs) therapy. In most cases, CML has become a chronic disease, requiring both long-term treatment and molecular monitoring, allowing patient life expectancy to approach that of the general population (1) and driving them to achieve deep molecular response (DMR) in a substantial number of cases (2). Evidence has shown that most CML patients in chronic phase (CP-CML) who have achieved a stable DMR can safely discontinue TKI treatment (3). However, in the clinical aspect, a proportion of CP-CML patients had to change TKIs treatment due to the occurrence of adverse events, thus affecting the achievement of either clinical or molecular responses (4).The classic trial International Randomized Study of Interferon and STI571 (IRIS) compared interferon-alpha combined with low-dose cytarabine therapy to imatinib (IM) 400 mg daily in newly-diagnosed CP-CML patients (5). In that investigation IM displayed markedly superior rates of complete hematological response, complete cytogenetic response (CCyR), major molecular response (MMR) and freedom from disease progression to advanced phases. In the long term, patients assigned to the IM group showed an estimated overall survival rate of 83.3% at 10 years (6). At 5 years of follow-up 49.9% of the patients had a CCyR, 50.3% of them reached a MMR and 23% a deep molecular response (MR 4.5 ), while at 10 years of follow-up 34.4% of patients displayed a MMR and 23.3% had a MR 4.5 (all data on intention to treat population). However, at the las...